Novo Nordisk A/S (NYSE:NVO) Stock Holdings Raised by Bfsg LLC

Bfsg LLC raised its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 18.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 102,992 shares of the company's stock after purchasing an additional 16,375 shares during the quarter. Novo Nordisk A/S comprises approximately 1.0% of Bfsg LLC's holdings, making the stock its 22nd biggest holding. Bfsg LLC's holdings in Novo Nordisk A/S were worth $8,859,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. WCM Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 1.0% in the 4th quarter. WCM Investment Management LLC now owns 4,031,124 shares of the company's stock valued at $345,588,000 after purchasing an additional 40,475 shares during the last quarter. Natixis Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company's stock valued at $366,125,000 after purchasing an additional 80,070 shares during the last quarter. International Assets Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. LPL Financial LLC boosted its holdings in shares of Novo Nordisk A/S by 3.6% in the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company's stock valued at $162,266,000 after purchasing an additional 47,496 shares during the last quarter. Finally, DAVENPORT & Co LLC lifted its holdings in shares of Novo Nordisk A/S by 75.1% during the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company's stock valued at $90,477,000 after acquiring an additional 451,641 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

NVO has been the topic of several recent research reports. Cantor Fitzgerald restated an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Moderate Buy" and an average target price of $145.25.

Novo Nordisk A/S Stock Up 5.2 %

Novo Nordisk A/S stock traded up $4.33 during midday trading on Friday, hitting $88.07. 15,117,993 shares of the stock were exchanged, compared to its average volume of 9,263,626. Novo Nordisk A/S has a 1 year low of $77.82 and a 1 year high of $148.15. The firm has a market cap of $395.19 billion, a P/E ratio of 26.77, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company has a 50 day moving average price of $86.01 and a two-hundred day moving average price of $108.22.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a $0.7874 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's payout ratio is presently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.